CA2901795C - Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment - Google Patents

Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment Download PDF

Info

Publication number
CA2901795C
CA2901795C CA2901795A CA2901795A CA2901795C CA 2901795 C CA2901795 C CA 2901795C CA 2901795 A CA2901795 A CA 2901795A CA 2901795 A CA2901795 A CA 2901795A CA 2901795 C CA2901795 C CA 2901795C
Authority
CA
Canada
Prior art keywords
cancer
peg
adi
therapeutic composition
arginine deiminase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2901795A
Other languages
English (en)
French (fr)
Other versions
CA2901795A1 (en
Inventor
Robert Almassy
Richard E. Showalter
James A. Thomson
Wes SISSON
Wei-Jong SHIA
Li-Chang Chen
Yang Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polaris Group Cayman Islands
Original Assignee
Polaris Group Cayman Islands
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polaris Group Cayman Islands filed Critical Polaris Group Cayman Islands
Publication of CA2901795A1 publication Critical patent/CA2901795A1/en
Application granted granted Critical
Publication of CA2901795C publication Critical patent/CA2901795C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2901795A 2013-03-15 2014-03-13 Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment Active CA2901795C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790833P 2013-03-15 2013-03-15
US61/790,833 2013-03-15
PCT/US2014/026766 WO2014151982A2 (en) 2013-03-15 2014-03-13 Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment

Publications (2)

Publication Number Publication Date
CA2901795A1 CA2901795A1 (en) 2014-09-25
CA2901795C true CA2901795C (en) 2022-08-02

Family

ID=51581665

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2901795A Active CA2901795C (en) 2013-03-15 2014-03-13 Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Country Status (12)

Country Link
US (2) US11235037B2 (cg-RX-API-DMAC7.html)
EP (2) EP3744341A1 (cg-RX-API-DMAC7.html)
JP (1) JP6382934B2 (cg-RX-API-DMAC7.html)
KR (2) KR102263038B1 (cg-RX-API-DMAC7.html)
CN (1) CN105188739B (cg-RX-API-DMAC7.html)
AU (1) AU2014236653B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015021483A2 (cg-RX-API-DMAC7.html)
CA (1) CA2901795C (cg-RX-API-DMAC7.html)
ES (1) ES2805360T3 (cg-RX-API-DMAC7.html)
RU (1) RU2015141932A (cg-RX-API-DMAC7.html)
SG (1) SG11201507354QA (cg-RX-API-DMAC7.html)
WO (1) WO2014151982A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014521602A (ja) 2012-04-04 2014-08-28 ポラリス グループ アルギニンデイミナーゼを用いる処置方法
WO2014151982A2 (en) 2013-03-15 2014-09-25 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
WO2015143006A1 (en) * 2014-03-18 2015-09-24 Tdw Group Engineered chimeric pegylated adi and methods of use
TWI790481B (zh) 2014-07-08 2023-01-21 開曼群島商瑞華藥業集團 精胺琥珀酸合成酶之抗體及相關方法
CA2961602A1 (en) 2014-09-16 2016-03-24 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
TWI699210B (zh) * 2015-03-18 2020-07-21 開曼群島商瑞華藥業集團 工程化之嵌合聚乙二醇化adi及使用方法
US12281339B2 (en) 2016-07-05 2025-04-22 Polaris Group Combination cancer immunotherapies with arginine depletion agents
EP3534963B1 (en) 2016-11-02 2024-04-17 Polaris Group Formulations of pegylated arginine deiminase
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
US12344645B2 (en) * 2017-03-29 2025-07-01 Polaris Group Protein conjugates
CN108324951B (zh) * 2018-04-16 2021-05-25 薛剑峰 一种精氨酸脱亚胺酶注射剂及其制备方法
EP4580657A4 (en) * 2022-09-02 2026-02-18 Polaris Group Modified Arginine Deiminases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
US5804183A (en) 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US6635462B1 (en) * 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
US6180387B1 (en) 1997-08-11 2001-01-30 Smithkline Beecham Corporation Arginine deiminase
IT1298918B1 (it) 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
WO2002009741A1 (en) * 2000-07-27 2002-02-07 Angiolab, Inc. The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
AU2001289132A1 (en) 2000-11-28 2002-06-11 Phoenix Pharmacologics, Inc. Modified arginine deiminase
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
ES2477118T3 (es) * 2002-11-18 2014-07-15 Polaris Group Método para inhibir la replicaci�n viral in vivo
AU2004235382A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing AML and MDS differential gene expression
US20070212311A1 (en) 2003-10-07 2007-09-13 University Of Florida Research Foundation, Inc. Recombinant Alkalinizing Bacteria
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
WO2009006590A2 (en) 2007-07-04 2009-01-08 Dr. Reddy's Laboratories Ltd. Docetaxel process and polymorphs
US20090238813A1 (en) * 2007-12-28 2009-09-24 Board Of Regents, The University Of Texas System Compositions And Methods For Engineered Human Arginine Deiminases
US20120015049A1 (en) 2009-01-14 2012-01-19 Lin Zhang Microrna biomarker in cancer
WO2011053871A2 (en) * 2009-10-30 2011-05-05 Life Technologies Corporation Multi-primer assay for mycoplasma detection
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
PL394618A1 (pl) 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
FR2978416B1 (fr) 2011-07-26 2013-11-29 Decathlon Sa Vehicule, par exemple du type trottinette, avec systeme de repliage
US8663967B2 (en) * 2011-08-22 2014-03-04 Jiangsu T-Mab Biopharma Co., Ltd. Arginine deiminase mutant and preparation and application thereof
JP2014521602A (ja) 2012-04-04 2014-08-28 ポラリス グループ アルギニンデイミナーゼを用いる処置方法
WO2014151982A2 (en) 2013-03-15 2014-09-25 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
WO2015143006A1 (en) 2014-03-18 2015-09-24 Tdw Group Engineered chimeric pegylated adi and methods of use
CA2961602A1 (en) 2014-09-16 2016-03-24 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Also Published As

Publication number Publication date
US20140348814A1 (en) 2014-11-27
EP2968482A4 (en) 2016-07-20
KR20210069126A (ko) 2021-06-10
JP2016519069A (ja) 2016-06-30
US11235037B2 (en) 2022-02-01
US20220105160A1 (en) 2022-04-07
WO2014151982A2 (en) 2014-09-25
KR102455753B1 (ko) 2022-10-17
JP6382934B2 (ja) 2018-08-29
HK1219232A1 (zh) 2017-03-31
CA2901795A1 (en) 2014-09-25
CN105188739B (zh) 2017-06-23
WO2014151982A3 (en) 2015-01-08
EP2968482A2 (en) 2016-01-20
KR20150129728A (ko) 2015-11-20
EP2968482B1 (en) 2020-05-06
HK1214139A1 (en) 2016-07-22
EP3744341A1 (en) 2020-12-02
SG11201507354QA (en) 2015-10-29
KR102263038B1 (ko) 2021-06-14
AU2014236653A1 (en) 2015-09-10
ES2805360T3 (es) 2021-02-11
RU2015141932A (ru) 2017-04-26
CN105188739A (zh) 2015-12-23
BR112015021483A2 (pt) 2017-10-10
AU2014236653B2 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
AU2014236653B2 (en) Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment
EP4104853B1 (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
CA2834083A1 (en) Compositions comprising pegylated arginine deiminase
TWI676683B (zh) 用於癌症治療之對adi-peg20抗體交叉反應性降低之精胺酸去亞胺酶
HK40041474A (en) Arginine deiminase with reduced cross-reactivity toward adi-peg 20 antibodies for cancer treatment
HK1214139B (en) Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
HK40075284A (zh) 用於癌症治疗的对adi-peg20抗体具有降低的交叉反应性的精氨酸脱亚氨酶
HK40128276A (en) Composition comprising pegylated arginine deiminase
HK40075284B (en) Arginine deiminase with reduced cross-reactivity toward adi-peg 20 antibodies for cancer treatment
HK1219232B (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190307

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241212

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202